Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07256405Active Not Recruiting

Metagenomic Next-Generation Sequencing for the Diagnosis of Fracture-related Infection

Role: collaborator

NCT07229677Recruiting

Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.

Role: collaborator

NCT04816760Unknown

Immune Cells Phenotypes During COVID-19

Role: lead

NCT02413905Completed

Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition

Role: lead

NCT02407275Not ApplicableUnknown

Rhinosinusites Chroniques

Role: lead

All 5 trials loaded